Apogee Therapeutics, Inc. (APGE)

NGM – Цена в реальном времени. Валюта: USD

82.93

-1.67 (-1.97%)

При закрытии: May 12, 2026, 4:00 PM EDT

83.43

+0.50 (0.60%)

До открытия: May 13, 2026, 5:38 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Apogee Therapeutics, Inc. (APGE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Видео

No Data

Пресс-релизы

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Search stocks

Apogee Therapeutics, Inc. (APGE)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Apogee Therapeutics, Inc. (APGE)

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy

Apogee Therapeutics: 'Strong Buy' As Zumilokibart Progresses To Next Q2 Milestone

Apogee Therapeutics, Inc. (APGE) Discusses 52-Week Phase 2 APEX Data for Zumilokibart in Moderate to Severe Atopic Dermatitis Transcript

Видео

No Data

Пресс-релизы

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering